Aptevo Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

APVO$1.13-8.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts, unaudited)

	September 30, 2024	December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$7,753	$16,904
Prepaid expenses	1,635	1,473
Other current assets	624	689
Total current assets	10,012	19,066
Property and equipment, net	614	895
Operating lease right-of-use asset	4,520	4,881
Total assets	$15,146	$24,842
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued liabilities	$3,532	$3,984
Accrued compensation	922	2,098
Other current liabilities	1,428	1,142
Total current liabilities	5,882	7,224
Other long-term liabilities	14	—
Operating lease liability	4,830	5,397
Total liabilities	10,726	12,621
Stockholders' equity:
Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding	—	—
Common stock: $0.001 par value; 500,000,000 shares authorized; 17,050,536 and 442,458 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	82	61
Additional paid-in capital	245,603	235,607
Accumulated deficit	(241,265)	(223,447)
Total stockholders' equity	4,420	12,221
Total liabilities and stockholders' equity	$15,146	$24,842

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.